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Recently, it was shown that t(10;16)(q22;p13) fuses the MORF and CREBBP genes in a case of childhood acute myeloid leukemia
(AML) M5a, with a complex karyotype containing other rearrangements. Here, we report a new case with the MORF-CREBBP
fusion in an 84-year-old patient diagnosed with AML M5b, in which the t(10;16)(q22;p13) was the only cytogenetic aberration.
This supports that this is a recurrent pathogenic translocation in AML. © 2003 Wiley-Liss, Inc.
Some acquired chromosomal abnormalities re-
sulting in fusion genes characterize acute myeloid
leukemias (AMLs) and their detection is important
for the clinical management and to uncover the
molecular basis of the disease. Recently, it was
shown that the t(10;16)(q22;p13) fuses MORF and
CREBBP genes in a case of childhood AML M5a
(Panagopoulos et al., 2001). CREBBP is a large
nuclear protein and a transcriptional coactivator,
implicated in hematopoiesis, which physically in-
teracts with various sequence-speciﬁc DNA-bind-
ing factors through conserved domains (McManus
and Hendzel, 2001; Blobel, 2002; Cantor and Or-
kin, 2002). Mutations and constitutional transloca-
tions affecting the CREBBP gene, located at 16p13,
are responsible for RubinsteinTaybi syndrome
(RTS), a complex developmental disorder that
leads to an increased incidence of neoplasia (Petrij
et al., 1995, 2000). CREBBP is also rearranged with
MOZ in leukemias with the t(8;16)(p11;p13) (Bor-
row et al., 1996; Chaffanet et al., 1999; Panagopou-
los et al., 2000a) and with MLL in hematologic
malignancies with t(11;16)(q23;p13) (Rowley et al.,
1997; Satake et al., 1997; Sobulo et al., 1997; Taki
et al., 1997; Sugita et al., 2000). MORF (monocytic
leukemia zinc ﬁnger protein-related factor) is a
ubiquitously expressed gene, located at 10q22,
which displays a high degree of similarity with
MOZ and which also contains zinc ﬁngers, a histone
acetyltransferase (HAT) domain, an acidic region,
and a COOH-terminal Ser/Met-rich domain
(Champagne et al., 1999).
We report here a t(10;16)(q22;p13), with a
MORF-CREBBP fusion, as the only cytogenetic
abnormality in an AML M5b. This is the second
case of such a translocation reported in the litera-
ture, suggesting that this translocation is a recur-
rent event in AML.
An 84-year-old patient was admitted to the hos-
pital because of pain in the left upper limb irradi-
ating to the ﬂank and a ﬂulike syndrome. The
peripheral blood values were hemoglobin 13.6
g/100 ml, platelets 10.9  109/L, and WBC count
24.5  109/L with 33% blasts. The bone marrow
aspirate was almost completely inﬁltrated with
atypical cells (89% monocytes). Bone marrow cyto-
genetics showed a t(10;16)(q22;p13) in 100% of the
metaphases (38/38) as the only aberration (Fig. 1A).
A diagnosis of AML M5b was made. The patient
received no curative intended treatment, and died
one month later.
One patient with AML (M4) with a similar trans-
location t(10;16)(q21;p13), showing also an 11q23
rearrangement, was previously reported (Pebusque
et al., 1988), although molecular studies were not
performed. Recently, a 4-year-old girl with AML
M5a was reported (Panagopoulos et al., 2001) with
a complex karyotype including a t(10;16)(q22;p13).
Fluorescence in situ hybridization (FISH) and mo-
lecular analyses showed that the t(10;16)(q22;p13)
resulted in a fusion between MORF and CREBBP.
This ﬁnding prompted us to investigate whether
the same fusion gene could be present also in our
patient.
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Reverse transcriptase–polymerase chain reaction
(RT-PCR) analysis was performed as reported by
Panagopoulos et al. (2001). One-step RT-PCR with
primers MORF2843F and CBP425R was done as
described and yielded the expected 0.4-kb frag-
ment, showing the presence of the MORF-
CREBBP fusion gene (Fig. 2A). Nested RT-PCR
with primers CBP96F/MORF3383R and CBP174F/
MORF3277R was necessary (Panagopoulos et al.,
2001) to amplify the expected 0.3-kb fragment cor-
responding to the reciprocal CREBBP-MORF tran-
script (Fig. 2A). Sequence analysis of the MORF-
CREBBP ampliﬁcation product showed that the
translocation fused MORF exon 15 with CREBBP
exon 3 (Fig. 2B). Thus, the breakpoints in our case
led to the fusion of the same exons as described in
the previously reported patient. FISH analysis of
bone marrow cells with bacterial artiﬁcial chromo-
somes (BACs) RPCI-11 461A8 and RPCI-11 95J11
(Fig. 1B) was consistent with the disruption of the
CREBBP gene in this region because the split
affected 95J11, which covers the initial part of the
gene.
The present case displays some features in com-
mon with the one published by Panagopoulos et al.
(2001). Both were diagnosed as AML M5 and the
breakpoints led to fusion of the same exons of
MORF and CREBBP. However, the case published
previously was a 4-year-old girl who was alive at the
time of publication. We report an 84-year-old male
who died one month later. Furthermore, the t(10;
16)(q22;p13) was not the only cytogenetic aberra-
tion in the previous case. Hence, it was unclear
whether the MORF-CREBBP fusion was responsi-
ble for the development of leukemia. In our pa-
tient, the t(10;16) was the sole cytogenetic event in
leukemic cells, suggesting that the fusion gene
could contribute directly to the development of the
AML.
MORF is very similar to MOZ, a gene fused to
CREBBP in t(8;16)(p11;p13) (Borrow et al., 1996;
Chaffanet et al., 1999; Panagopoulos et al., 2000a),
TIF2 in inv(8)(p11q13) (Carapeti et al., 1998, 1999;
Liang et al., 1998; Panagopoulos et al., 2000b; Billio
et al., 2002), and to EP300 in t(8;22)(p11;q13)
(Chaffanet et al., 2000; Kitabayashi et al., 2001).
Fusion genes involving MOZ are mainly seen in
young patients with AML M4/M5, in which the
leukemic blasts frequently display erythrophagocy-
tosis. Thus, it is frequently associated with certain
morphological and clinical features irrespective of
the partner gene. However, despite the similarities
between MOZ and MORF, the morphological anal-
ysis of bone marrow aspirate from our patient did
not reveal any signs of erythrophagocytosis. Unlike
the case with inv(8)(p11q13) and MOZ-TIF2 fusion
recently published (Billio et al., 2002), the case
reported here was negative for the FLT3-ITD (Na-
kao et al., 1996) and D835 mutation (Yamamoto et
al., 2001) (data not shown).
Figure 1. G-Band and FISH analyses. A: Partial karyotype showing the t(10;16)(q22;p13). Arrows
indicate breakpoints. B: FISH analysis by use of BACs RPCI-11 461A8 (green) and RPCI-11 95J11 (red)
showing that the signal of 95J11, which covers the initial part of the CREBBP gene, is split between der(10)
and der(16). [Color ﬁgure can be viewed in the online issue, which is available at www.interscience.wiley.
com.]
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In both patients with the t(10;16)(q22;p13) de-
scribed to date, both MORF-CREBBP and
CREBBP-MORF transcripts were detected. It is
not yet clear which of them is mainly responsible
for the leukemogenic effect, but it has been sug-
gested that this results from the substitution of the
COOH-terminal part of MORF or MOZ by the
COOH-terminal part of CREBBP, P300 or TIF2.
As in the previously reported patient, a one-step
RT-PCR was sufﬁcient to detect the MORF-
CREBBP transcript, whereas a nested RT-PCR
was necessary to detect CREBBP-MORF. This
could indicate that the transcription level of the
former transcript is higher.
In summary, we report an 84-year-old patient
with AML M5b showing a t(10;16)(q22;p13) as the
sole cytogenetic aberration, with the presence of
MORF-CREBBP and CREBBP-MORF fusion tran-
scripts. This case, the second one reported thus far,
proves that this is a recurrent pathogenic event in
AML.
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